Regeneron Pharmaceuticals Faces Class Action Lawsuit Over Failed Melanoma Trial Results

Legal Alert: Regeneron Pharmaceuticals Class Action Lawsuit

On September 14, 2026, Hagens Berman Sobol Shapiro LLP alerted investors regarding a securities class action lawsuit against Regeneron Pharmaceuticals (NASDAQ: REGN) following alarming news about a Phase 3 clinical trial aimed at finding a treatment for melanoma. The fallout from the trial’s failure not only affected investor confidence but also saw Regeneron suffer a staggering $11 billion drop in its market capitalization.

The lawsuit aims to represent investors who bought shares of Regeneron stock from August 1, 2025, to May 15, 2026, during a period when the company consistently projected optimism about the success of its clinical trials. Investors are encouraged to report their losses, especially those who may have additional information regarding the case.

The class action focuses on the fiduciary responsibilities that Regeneron failed to meet, including maintaining transparency with its investors about the clinical trial’s progress and altering the protocol without timely disclosure. The failed trial, involving the drug Fianlimab in combination with Libtayo, was aimed at treating advanced melanoma—a condition that demands substantial research and financial resources.

The primary endpoint of the trial was to assess progression-free survival (PFS) rates among patients. Regeneron proudly projected this treatment as a potential blockbuster, yet the lawsuit alleges that they failed to disclose critical flaws in the statistical assumptions of the trial. Specifically, it claims that Regeneron did not inform investors that the active treatment wasn't performing adequately against standard therapies, and achieving key trial endpoints was increasingly unlikely.

Throughout the specified class period, Regeneron executives repeatedly assured shareholders that the trial was on track, even as signs indicated otherwise. Notably, a management statement suggested that dwindling patient responses indicated competence in treatment arms, a claim that others in the field were slow to accept as accurate.

The truth about the trial's shortcomings began surfacing on April 29, 2026, when Regeneron announced changes to the trial's protocols that would impact how patient data was analyzed. A highly regarded analyst publicly questioned whether these changes were indicative of underlying issues in patient responses, particularly given the slow progression of events.

By May 12, 2026, Regeneron further admitted that the protocol adjustments were necessitated by sluggish event rates, which had initially caused significant concern about the trial’s validity. Ultimately, on May 15, 2026, Regeneron shocked the investment community by confirming that the trial had not reached statistical significance concerning PFS improvements, effectively crashing investor confidence.

Reed Kathrein, a partner at Hagens Berman, highlighted the firm's commitment to discerning whether Regeneron had intentionally misled investors about the trial outcomes and the actual potential of the drug combination.